Plasmid DNA Contamination: A Primer – Part 2

Read Part 1

Kevin McKernan, a scientist known for his work in genomics, has been sounding the alarm recently on Pfizer’s controversial vaccine production process, and the failure to disclose manufacturing switches from regulators, putting our health at risk – at warp speed.

Let’s continue with the long list of issues….

Below we will cover:

Elderly Population
Trial Blinding
Batch Variability
Placebo Group
Lot Numbers and Distribution
Regulatory and Manufacturing Processes
Lipid nanoparticles (LNPs)
SV40 (Simian Virus 40) Promoter
Open Reading Frames
Impact of Modifications

Elderly Population: It’s mentioned that there were no plans to test these vaccine batches on the elderly population, despite the higher risks COVID-19 poses to them.

Trial Blinding: The trial was “observer-blinded” rather than “double-blinded,” meaning that those administering the vaccine knew who was receiving it, which could potentially introduce bias.

Batch Variability: There is speculation about variability in adverse event rates associated with different manufacturing processes (process one and process two) and possibly even within lots from the same process, which might affect the vaccine’s safety profile.

Placebo Group: When those originally in the placebo group started receiving the actual vaccine, there seemed to be a higher rate of adverse events compared to the initial treatment group, which could be due to several factors, including the possibility that they were more likely to report symptoms knowing they received the vaccine.

Lot Numbers and Distribution: According to batch numbers and the distribution to various sites, there is an implication that certain batches may have been linked to a higher incidence of adverse reactions.